The unparalleled genetic tractability of the murine model makes it the definitive system for interrogating complex disease pathways, validating novel targets, and establishing proof-of-concept efficacy. BioLegacy harnesses the full power of this platform, offering deep expertise across a vast portfolio of well-characterized induced and genetically engineered mouse models. Biolegacy works with all National breeders and can procure immunocompromised animals or genetically modified mice from dedicated partner labs. Our large and extensively validated portfolio of mouse models provides robust data for the most demanding therapeutic areas, particularly immuno-oncology and immunology. What you get is definitive, mechanistic data to de-risk your program and accelerate your most promising candidates.
- Immuno-Oncology Studies: Comprehensive syngeneic tumor models to evaluate checkpoint inhibitors, CAR-T, and other immunomodulators in the context of a competent immune system.
- Broad Oncology Capabilities: Orthotopic, ectopic, and metastatic models. 100s of tumor cell lines available.
- Genetically Engineered Models (GEMs): Extensive expertise in study design and execution using knockout, knock-in, and transgenic lines for complex target validation.
- Humanized Mouse Models: Advanced platforms reconstituted with human immune systems (e.g., huCD34+) or expressing human transgenes for evaluating human-specific biologics.
- Autoimmunity & Inflammation Expertise: Robust, well-characterized models for autoimmune diseases like rheumatoid arthritis (CIA), multiple sclerosis (EAE), and inflammatory bowel disease (IBD).
- Comprehensive Bioanalytical & Biomarker Integration: Seamless in-house support for correlating PK/PD analysis, including immunophenotyping using flow cytometry and multiplex cytokine analysis.
- A Plethora of Therapeutic Areas: Oncology, immunology, dermatology, neurology, metabolism, gastroenterology, pulmonology, urology, infectious disease, and more.
